Checked
Interpace Biosciences, Inc.
OTC: IDXG · Surgical & Medical Instruments & Apparatus · Parsippany, NJ
- Revenue
- $38.73M
- -17.5% vs. prior year
- Net income
- $24.57M
- 63.5% net margin
- Total assets
- $33.84M
- Diluted EPS
- $0.89
Company details
As reported to the SEC
- SEC CIK
- 1054102
- Stock
- OTC: IDXG
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus (3841)
- Headquarters
- Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (412) 224-6100
- Employer ID (EIN)
- 22-2919486
- Last annual report
- 03/30/2026
- Last quarterly report
- 08/10/2026
Formerly: Interpace Diagnostics Group, Inc. (until 11/01/2019); PDI INC (until 12/22/2015); PROFESSIONAL DETAILING INC (until 11/13/2002)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $38.73M | $46.93M | $40.04M | $5.68M | $8.2M |
| Gross profit | $24.13M | $29.93M | $25.06M | $18.23M | $18.8M |
| Operating income | $4.08M | $8.11M | $3.96M | -$3.62M | -$6.34M |
| Net income | $24.57M | $6.7M | $1.95M | -$21.96M | -$14.94M |
| Diluted earnings per share | $0.89 | $0.40 | $0.45 | -$5.18 | -$3.61 |
| Research and development | $642K | $676K | $636K | $703K | $1.49M |
| Total assets | $33.84M | $14.79M | $13.12M | $15.98M | $38.43M |
| Total liabilities | $11.47M | $17.01M | $22.12M | $32.52M | $34.31M |
| Shareholders' equity | $22.36M | -$2.22M | -$55.54M | -$58.09M | -$42.42M |
| Cash and cash equivalents | $2.5M | $1.46M | $3.5M | $4.83M | $2.67M |
| Cash from operations | $5.83M | $4.65M | $3.79M | -$7.69M | -$8.72M |
| Capital expenditures | $356K | $876K | $470K | $322K | $354K |
Federal and state records filed under the name Interpace Biosciences, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Interpace Biosciences, Inc.Parsippany, NJ | 0 | 1 |
Recent filings
183 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| FWPFree writing prospectus | 10/15/2026 | None |
| 8-KResults of operations | 10/15/2026 | 10/14/2026 |
| S-1/ARegistration statement (amended) | 10/01/2026 | None |
| S-1Registration statement (new securities) | 09/25/2026 | None |
| S-8Registration of employee stock plan shares | 09/17/2026 | None |
| 8-KBylaws or fiscal year change, Regulation FD disclosure | 08/27/2026 | 08/27/2026 |
| 8-K/ADirector or officer change | 08/26/2026 | 08/20/2026 |
| 8-KShareholder vote results | 08/21/2026 | 08/20/2026 |
| 8-KResults of operations | 08/12/2026 | 08/10/2026 |
| 10-QQuarterly report | 08/10/2026 | 06/30/2026 |
| DRSSEC filing | 07/22/2026 | None |
| DEFA14AAdditional proxy materials | 07/07/2026 | None |
| DEF 14AProxy statement | 07/07/2026 | 07/07/2026 |
| PREM14ASEC filing | 06/25/2026 | 06/24/2026 |
| PRE 14APreliminary proxy statement | 06/23/2026 | 06/23/2026 |
| 8-KResults of operations | 05/14/2026 | 05/12/2026 |
| 10-QQuarterly report | 05/12/2026 | 03/31/2026 |
| 10-K/AAnnual report (amended) | 04/30/2026 | 12/31/2025 |
| 8-KResults of operations | 04/01/2026 | 03/30/2026 |
| 10-KAnnual report | 03/30/2026 | 12/31/2025 |
8 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Interpace Biosciences, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other surgical & medical instruments & apparatus
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Medline Inc.MDLN | Northfield, IL | $28.43B | $1.16B |
| Stryker CorpSYK | Portage, MI | $25.12B | $3.25B |
| 3m CoMMM | St Paul, MN | $24.95B | $3.25B |
| Becton Dickinson & CoBDX | Franklin Lakes, NJ | $21.84B | $1.68B |
| Boston Scientific CorpBSX | Marlborough, MA | $20.07B | $2.89B |
| Baxter International IncBAX | Deerfield, IL | $11.24B | -$957M |
| Solventum CorpSOLV | Eagan, MN | $8.32B | $1.56B |
| Resmed IncRMD | San Diego, CA | $5.65B | $1.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Interpace Biosciences, Inc.'s CIK number?
- Interpace Biosciences, Inc.'s SEC Central Index Key (CIK) is 1054102.
- What is Interpace Biosciences, Inc.'s stock ticker?
- Interpace Biosciences, Inc. trades as OTC: IDXG.
- What was Interpace Biosciences, Inc.'s revenue?
- Interpace Biosciences, Inc. reported revenue of $38.73M for the fiscal year ended Dec 31, 2025, -17.5% from the year before.
- When does Interpace Biosciences, Inc.'s fiscal year end?
- Interpace Biosciences, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Interpace Biosciences, Inc. headquartered?
- Interpace Biosciences, Inc.'s principal executive office on file with the SEC is in Parsippany, NJ.
- Does Interpace Biosciences, Inc. sponsor H-1B visas?
- Department of Labor records show 0 certified H-1B filings and 1 certified PERM filings under the name Interpace Biosciences, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026